Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology · Autoimmune Nodopathies

Autoimmune Nodopathies: A Crucial Distinction

At a Glance

Autoimmune nodopathies are nerve diseases distinct from typical CIDP because the immune system attacks specific nerve gaps (Nodes of Ranvier) rather than the myelin. They often feature severe tremors, do not respond well to standard IVIG therapy, and are more effectively treated with rituximab.

In the world of CIDP, one of the most important scientific breakthroughs in recent years is the discovery of Autoimmune Nodopathies. For a long time, these were thought to be just another “type” of CIDP. However, the 2021 EAN/PNS guidelines now classify them as a completely distinct category of disease [1][2].

If you have been diagnosed with CIDP but find that standard treatments aren’t working, understanding this distinction could be the key to your recovery.

The Biology of the “Nodal” Attack

To understand autoimmune nodopathies, think back to the idea of nerves as insulated electrical wires. In typical CIDP, the immune system attacks the “plastic insulation” (myelin) [3].

In autoimmune nodopathies, the attack is more surgical. It targets the Nodes of Ranvier—tiny gaps in the insulation where the nerve signal “recharges” as it jumps down the wire [4]. These gaps are held together by specific proteins called NF155 (Neurofascin-155), CNTN1 (Contactin-1), and Caspr1 [5][6].

  • When antibodies attack these proteins, the gaps fall apart.
  • The nerve signal can no longer “jump,” causing it to slow down or stop entirely [7].
  • Unlike typical CIDP, there is often no widespread stripping of the myelin (demyelination) by immune cells; the damage is focused at these critical junctions [8][9].

Distinct Symptoms and “Red Flags”

Autoimmune nodopathies often look different from classic CIDP. Doctors look for these “red flags” to trigger specific antibody testing [10][11]:

  • Tremor: A visible, sometimes severe shaking of the hands [12][13].
  • Sensory Ataxia: Severe balance issues where you feel “uncoordinated” because your brain can’t tell where your limbs are [14][15].
  • Rapid Onset: Symptoms may come on more aggressively and severely than typical CIDP [13].
  • Poor Response to IVIG: This is a major clue. Because these antibodies are often of the IgG4 subclass, they do not respond well to standard intravenous immunoglobulin (IVIG) therapy [16][12].

Why the Label Matters: The Rituximab Connection

If you have an autoimmune nodopathy, the “gold standard” CIDP treatments (IVIG and steroids) may fail [17]. This is not because your disease is “untreatable,” but because it requires a different tool.

Because these diseases are driven by specific antibodies produced by B-cells, the most effective treatment is often a B-cell depletion therapy like rituximab [18][19]. Rituximab clears out the cells making the harmful antibodies, allowing the nerve junctions to repair themselves. For many patients who were previously told they were “treatment-resistant,” switching to rituximab has led to significant clinical improvement [17][20].

Important Safety Note: Because rituximab is a powerful immunosuppressant, it is important to ensure all your vaccines (especially pneumococcal, flu, and COVID-19) are up to date before starting, as the medication severely blunts your ability to respond to new vaccines, making you more vulnerable to infections [17].

Auditing Your Records

You can play an active role in your diagnosis by checking your medical records. Look for a lab report called a “Nodal/Paranodal Antibody Panel” or a “Neuropathy Antibody Panel.”

  • What to look for: Search for the terms NF155, CNTN1, Caspr1, or Neurofascin [21][11].
  • The Result: If these are listed as “Negative,” you likely have standard CIDP. If any are “Positive,” you should promptly reach out to your neurologist or bring this up as a priority at your next appointment to discuss a potential change in diagnosis and treatment strategy [22].

Common questions in this guide

What is the difference between an autoimmune nodopathy and typical CIDP?
In typical CIDP, the immune system attacks the myelin insulation covering the entire nerve. In autoimmune nodopathies, the attack is focused specifically on the Nodes of Ranvier, which are the tiny gaps in the insulation necessary for nerve signals to travel.
Why is my CIDP not responding to IVIG treatment?
A poor response to standard IVIG or steroid therapy is a major sign that you might actually have an autoimmune nodopathy. These conditions are often driven by specific IgG4 antibodies, which generally do not improve with typical CIDP medications.
What tests are used to diagnose an autoimmune nodopathy?
Your neurologist can order a Nodal or Paranodal Antibody Panel. This specialized blood test checks for antibodies attacking specific nerve proteins, typically listed as NF155, CNTN1, and Caspr1.
How are autoimmune nodopathies treated?
Because these conditions are driven by harmful antibodies produced by B-cells, B-cell depletion therapy is often the standard of care. Medications like rituximab clear out these specific cells, allowing the damaged nerve junctions time to repair themselves.
What are the common symptoms of an autoimmune nodopathy?
Patients often experience severe hand tremors and sensory ataxia, which is a profound loss of balance because the brain loses track of where the limbs are in space. The symptoms also tend to appear more rapidly and aggressively than typical CIDP.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have I been tested for nodal and paranodal antibodies, specifically NF155, CNTN1, and Caspr1?
  2. 2.Does my clinical presentation, such as my [hand tremor/sensory ataxia], suggest an autoimmune nodopathy rather than typical CIDP?
  3. 3.If I have an IgG4-related autoimmune nodopathy, should we consider moving to a B-cell depletion therapy like rituximab earlier?
  4. 4.Why do autoimmune nodopathies often fail to respond to IVIG, and how does that affect our treatment strategy?
  5. 5.Are my vaccines up to date before we consider strong immunosuppressants?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

    Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

    European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

    PMID: 34327760
  2. 2

    How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast.

    Desai U

    Neurology and therapy 2023; (12(5)):1409-1417 doi:10.1007/s40120-023-00512-6.

    PMID: 37358694
  3. 3

    Complement profiling of sural nerves in chronic-inflammatory demyelinating polyneuropathy.

    Stascheit F, Roos A, Schroeter CB, et al.

    Acta neuropathologica 2025; (150(1)):32 doi:10.1007/s00401-025-02936-w.

    PMID: 40971018
  4. 4

    Autoimmune nodo-paranodopathies 10 years later: Clinical features, pathophysiology and treatment.

    Uncini A

    Journal of the peripheral nervous system : JPNS 2023; (28 Suppl 3()):S23-S35 doi:10.1111/jns.12569.

    PMID: 37272673
  5. 5

    Growing Spectrum of Autoimmune Nodopathies.

    Gupta P, Mirman I, Shahar S, Dubey D

    Current neurology and neuroscience reports 2023; (23(5)):201-212 doi:10.1007/s11910-023-01264-4.

    PMID: 37014546
  6. 6

    Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground.

    Uncini A, Vallat JM

    Journal of neurology, neurosurgery, and psychiatry 2018; (89(6)):627-635 doi:10.1136/jnnp-2017-317192.

    PMID: 29248893
  7. 7

    Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo.

    Manso C, Querol L, Lleixà C, et al.

    The Journal of clinical investigation 2019; (129(6)):2222-2236.

    PMID: 30869655
  8. 8

    Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.

    Tang L, Huang Q, Qin Z, Tang X

    Journal of neurology 2021; (268(8)):2757-2768 doi:10.1007/s00415-020-09823-2.

    PMID: 32266541
  9. 9

    Macrophages and Autoantibodies in Demyelinating Diseases.

    Koike H, Katsuno M

    Cells 2021; (10(4)) doi:10.3390/cells10040844.

    PMID: 33917929
  10. 10

    Clinical Features of Autoimmune Nodopathy With Anti-Neurofascin-155 Antibodies in South Koreans.

    Lyou HJ, Chung YH, Kim MJ, et al.

    Journal of clinical neurology (Seoul, Korea) 2024; (20(2)):186-193 doi:10.3988/jcn.2023.0055.

    PMID: 38171501
  11. 11

    Comparison of the presentation and electrophysiological characteristics of autoimmune nodopathies in patients with antibody-negative CIDP and CMT1.

    Song C, Liu H

    Frontiers in neurology 2025; (16()):1617545 doi:10.3389/fneur.2025.1617545.

    PMID: 41050276
  12. 12

    Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy.

    De Simoni D, Ricken G, Winklehner M, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2020; (7(4)) doi:10.1212/NXI.0000000000000763.

    PMID: 32487720
  13. 13

    Clinical characteristics of patients with autoimmune nodopathy with anti-neurofascin155 antibodies.

    Zhang J, Hou X, Wei L, et al.

    Frontiers in immunology 2024; (15()):1345953 doi:10.3389/fimmu.2024.1345953.

    PMID: 38726012
  14. 14

    Clinical characteristics of anti-neurofascin 155 antibody-positive autoimmune nodopathy in children.

    Cui L, Gong S, Zhao Y, et al.

    Pediatric investigation 2025; (9(3)):275-281 doi:10.1002/ped4.70008.

    PMID: 40969295
  15. 15

    [Clinical features of anti-neurofascin-155 antibody positive autoimmune nodopathy in 6 children].

    Fang ZX, Zhang M, Hu CP, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2024; (62(8)):780-785 doi:10.3760/cma.j.cn112140-20240228-00130.

    PMID: 39039882
  16. 16

    [Pathomechanism Underlying Intravenous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy].

    Shimizu F

    Brain and nerve = Shinkei kenkyu no shinpo 2024; (76(10)):1109-1118 doi:10.11477/mf.1416202746.

    PMID: 39370835
  17. 17

    The potential role of IgG subclass in NF155-associated nodopathy for targeting therapy: a pediatric case report highlighting the efficacy of pulsed oral corticosteroids.

    Turčanová Koprušáková M, Kurča E, Trusiková E, et al.

    BMC neurology 2025; (25(1)):451 doi:10.1186/s12883-025-04467-z.

    PMID: 41188793
  18. 18

    Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies.

    Dalakas MC

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):741-752 doi:10.1007/s13311-022-01210-1.

    PMID: 35290608
  19. 19

    Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response.

    Bresciani L, Salvalaggio A, Vegezzi E, et al.

    Journal of the peripheral nervous system : JPNS 2023; (28(3)):522-527 doi:10.1111/jns.12565.

    PMID: 37246762
  20. 20

    Clinical Manifestations and Treatment Responses in Pediatric Neurofascin 155-IgG4 Autoimmune Nodopathy.

    Rashed HR, Paramasivan NK, Selcen D, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2025; (12(2)):e200368 doi:10.1212/NXI.0000000000200368.

    PMID: 39823553
  21. 21

    Advances in the treatment of autoimmune nodopathy: based on treatment strategies of CIDP.

    Pang ZD, Sun H, Wei XJ, et al.

    Frontiers in immunology 2026; (17()):1735745 doi:10.3389/fimmu.2026.1735745.

    PMID: 41890726
  22. 22

    Autoimmune Nodopathy With Anti-Neurofascin 186 Antibody.

    Anilkumar A, Krishnan P

    Cureus 2025; (17(11)):e96112 doi:10.7759/cureus.96112.

    PMID: 41356854

This page provides educational information about autoimmune nodopathies and CIDP testing. It is not a substitute for professional medical advice; always consult your neurologist regarding specific antibody testing and treatment changes.

Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.